Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
Trial met both primary endpoints demonstrating statistically significant and clinically meaningful extension of progression free survival (PFS) as monotherapy vs. standard of care (SoC) endocrine...
-
BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET...
-
The wearABLe study did not demonstrate non-inferiority of abalo-TDS to TYMLOS®Lumbar spine BMD at 12 months vs. baseline for abalo-TDS was +7.1% vs. TYMLOS +10.9%Both abalo-TDS and TYMLOS 12-month...
-
BOSTON, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare...
-
TYMLOS® Q3, 2021 net revenue: $57 million, +13% vs. Q3, 2020Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included...
-
BOSTON, Oct. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday, Oct. 20, by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed...
-
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (NASDAQ: RDUS) announced today that it will release its third quarter financial results on Monday, November 8, 2021. The Company will...
-
Study met both primary endpoints in patients with ER+/HER2- advanced or mBCElacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the...
-
ATOM study met the primary endpoint of change in lumbar spine bone mineral density at 12 months (p-value < 0.0001)Study also met secondary endpoints relating to bone mineral density changes in...
-
TYMLOS® label: significant update to the Mechanism of Action (MOA) sectionLabel change aligns with strategic focus on postmenopausal women at high risk of fractureDanielle Holtschlag joins as Head of...